Do Traders Think ESSA Pharma Inc (EPIX) Can Keep Climbing Tuesday?

Overall market sentiment has been high on ESSA Pharma Inc (EPIX) stock lately. EPIX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

ESSA Pharma Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on EPIX!

See Full EPIX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With EPIX Stock Today?

ESSA Pharma Inc (EPIX) stock is up 22.6% while the S&P 500 is lower by -0.03% as of 1:33 PM on Tuesday, Oct 17. EPIX is higher by $0.73 from the previous closing price of $3.23 on volume of 492,704 shares. Over the past year the S&P 500 has gained 18.88% while EPIX is higher by 101.02%. EPIX lost -$0.62 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for ESSA Pharma Inc click here.

More About ESSA Pharma Inc

ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Click Here to get the full Stock Report for ESSA Pharma Inc stock.